Tiong A H, Richardson J S
Department of Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Canada.
Int J Neurosci. 1990 Oct;54(3-4):231-44. doi: 10.3109/00207459008986639.
(-)-[125I]Iodocyanopindolol [-]ICYP), is a ligand with high specific activity and nearly equal affinity for beta 1 and beta 2 adrenoceptors in a variety of tissues. Unfortunately, (-)ICYP also has affinity for 5HT1B serotonin receptors. To get an accurate estimate of beta adrenoceptors in the rat amygdala and hippocampus, (-)ICYP binding studies were done with membranes from these limbic structures in the presence of 10 microM serotonin to prevent the binding of (-)ICYP to serotonin receptors. Under these conditions. (-)ICYP binding to amygdaloid and hippocampus membrane preparations is saturable and reversible. Scatchard analyses revealed in both regions a single class of binding sites with an equilibrium dissociation constant (KD) of 18.5 pM for the amygdala and 19.6 pM for the hippocampus. The hippocampus has a significantly lower density of binding sites (Bmax) than amygdala (51.6 vs 62.3 fmol/mg membrane protein, p less than .05). The two brain regions do not differ with respect to kinetic reactions in that both show comparable slow association and dissociation rates. However, the dissociation reactions do reveal two affinity states for the binding sites in both areas. Detailed competition analyses with beta adrenoceptor subtype selective drugs (ICI-89406 and ICI-118551) show that in both regions about 70% of the beta adrenoceptor population is of the beta 1 subtype with the remainder being beta 2 subtype.
(-)-[¹²⁵I]碘氰吲哚洛尔([-]ICYP)是一种具有高比活性且对多种组织中的β1和β2肾上腺素能受体亲和力几乎相等的配体。不幸的是,(-)ICYP对5HT1B血清素受体也有亲和力。为了准确估计大鼠杏仁核和海马体中的β肾上腺素能受体,在10微摩尔血清素存在的情况下,用来自这些边缘结构的膜进行(-)ICYP结合研究,以防止(-)ICYP与血清素受体结合。在这些条件下,(-)ICYP与杏仁核和海马体膜制剂的结合是可饱和且可逆的。Scatchard分析显示,在这两个区域中均存在一类结合位点,杏仁核的平衡解离常数(KD)为18.5皮摩尔,海马体为19.6皮摩尔。海马体的结合位点密度(Bmax)明显低于杏仁核(分别为51.6和62.3飞摩尔/毫克膜蛋白,p小于0.05)。这两个脑区在动力学反应方面没有差异,因为两者都显示出相当的慢结合和解离速率。然而,解离反应确实揭示了这两个区域中结合位点的两种亲和力状态。用β肾上腺素能受体亚型选择性药物(ICI-89406和ICI-118551)进行的详细竞争分析表明,在这两个区域中,约70%的β肾上腺素能受体群体为β1亚型,其余为β2亚型。